tirzepatide surpass Efficacy and safety of monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial Flow of Participants in the

So as with obesity, this approval could very well open up a new era for sleep apnea treatment.

The SUMMIT trial (Packer et al, NEJM 2025) randomized 731 patients with HFpEF and obesity (mean BMI 38) to tirzepatide vs

BASE COURSE ON ULTRASOUND IMAGING WITH DAWN NAYLOR DNP, ACNP-BC, CANS & DR

Jain AB, Ali A, Gorgojo Martnez JJ, Hramiak I, Kavia K, Madsbad S, et al

Avoid alcohol or discuss very limited intake with your physician

| Thyroid monitoring and management | Important safety considerations | Frequently asked questions | Take home message You can take Wegovy (semaglutide) if you have an underactive thyroid (hypothyroidism) and your BMI is over 27